Gene Therapy Market: Global Industry Analysis and Forecast (2021-2027), Key Trends, Technology Trends, Market Share, Market Size.

Gene Therapy Market size is expected to grow from US$ 4.86 Bn. in 2020 to US$ 27.21 Bn. by 2027, growing at a CAGR of 27.9% through 2021 to 2027. Spinal Muscular Atrophy (SMA) Indication segment leads the Global Gene Therapy Market by 2027.

Global Gene Therapy Market Overview:

Global Gene Therapy market was valued at US $4.86 Bn. in 2020, and it is expected to reach US $27.21 Bn. by 2027 with a CAGR of 27.9% during the forecast period. In the last ten years, gene therapy and new treatments based on gene therapy have made significant progress. For certain disorders, clinically effective gene treatments have been produced, and many additional potential medications have been discovered, with this trend especially obvious in the field of haematological diseases. Delivery vectors, gene engineering methods, and application to chimeric antigen receptor (CAR) T cell therapy are only a few of the recent advances in gene therapy and gene therapy-based approaches. Global Gene Therapy Market To know about the Research Methodology :- Request Free Sample Report Though market forecasting through 2027 is based on real output, demand and supply of 2020, 2020 numbers are also estimated on real numbers published by key players as well all-important players across the world. Market forecasting till 2027 is done based on past data from 2016 to 2019 with the impact of global lock down on the market in 2020 and 2021.

Global Gene Therapy Market Dynamics:

The growing field of advanced therapeutics and gene delivery technologies has spawned a competitive environment in which a large number of market companies are attempting to commercialise their gene therapy products. Collaborations, mergers, and acquisitions are being considered by therapy developers as a potential option for enhancing in-house knowledge and strengthening product pipelines. These factors are expected to contribute to the market's growth. Although the high prices of currently accessible therapies encourage therapeutic development, they also limit accessibility and may lead to market withdrawals owing to the goods' lack of economic sustainability. As a result, a variety of payment methods, such as financial-based agreements and health-outcome-based agreements, have been proposed or implemented to improve therapy accessibility and market survival. These models have had a considerable impact on the market's uptake of medicines. Currently, the globe is attempting to offset the negative effects of the SARS-CoV-2 epidemic in order to restore market revenue flow. The cell and gene therapy industries have been severely hit. Progress in ongoing R&D has been slow since many universities have shut down and discontinued all non-essential research and enrolment processes for clinical trials. Biopharma companies, on the other hand, have taken a number of steps to establish a competitive advantage in the market. Companies are pursuing a variety of market entry methods, including growing biopharmaceutical facilities, collaborating with other important stakeholders, and developing products with Contract Manufacturing Organizations (CMOs). Univercells, for example, launched Exothera, a viral vector CDMO that supports cell and gene therapy companies, in March 2020.

Global Gene Therapy Market Segment Analysis:

Based on the Indication, the market is segmented into Acute Lymphoblastic Leukemia (ALL), Inherited Retinal Disease, Large B-cell Lymphoma, ADA-SCID, Melanoma (lesions), Beta-Thalassemia Major/SCD, Head & Neck Squamous Cell Carcinoma, Peripheral Arterial Disease, Spinal Muscular Atrophy (SMA), and Others. Spinal Muscular Atrophy (SMA) segment held the largest market share of 41% in 2020 and is expected to continue its dominance by 2027. Spinal Muscular Atrophy (SMA) is one of the most prevalent fatal hereditary disorders of childhood. The development of Zolgensma (AVXS-101) as a gene therapy has demonstrated its efficacy in treating SMA and modifying the disease phenotype. The FDA granted Novartis approval for Zolgensma, a drug aimed to treat the underlying cause of SMA, in May 2019. In this segment, Zolgensma is the first and only approved gene treatment. Global Gene Therapy Market Based on the Vector Type, the market is segmented into Lentivirus, AAV, Retrovirus & gamma Retrovirus, Modified Herpes Simplex Virus, Adenovirus, and Non-viral Plasmid Vector. AAV segment is expected to grow rapidly at a CAGR of xx% during the forecast period 2021-2027. AAV segment held the largest market share of 43% in 2020. The use of AAV has increased significantly in recent years across a variety of therapeutic fields, resulting in tremendous demand in the coming years. One of the most crucial aspects driving their adoption is their proven non-pathogenicity. Dimension Therapeutics, AGTC, Spark Therapeutics, Sangamo Biosciences, Biogen, and AveXis are among the companies working on AAV viral vector-based gene therapy research and development. Lentiviruses, on the other hand, are expected to be the fastest-growing vector-type segment from 2021 to 2027. This can be attributable to increased investments in this vector type by companies and research organizations following the approval of Zynteglo in 2019 and Kymriah in 2017. In addition, the availability of companies that provide an exclusive lentivector platform is increasing revenue development in this area. Oxford Biomedica Plc, for example, has an exclusive lentivector technology, which is an innovative and safe gene delivery technique. Global Gene Therapy Market

Global Gene Therapy Market Regional Insights:

North America dominates the Global Gene Therapy market during the forecast period 2021-2027. North America held the largest market share of 55% in 2020 and is expected to continue its dominance by 2027. The North American gene therapy business is booming due to increased insurance coverage, the presence of R&D institutions and institutes, and government funding. The market's growth is also influenced by well-established healthcare infrastructure and accessibility. The market's growth has been aided by investments from key players in the industry. The market for technologically advanced diagnostic imaging systems for gene therapy is rapidly growing due to rising use. Furthermore, the approval of Zolgensma in 2019 benefited the US market tremendously. Asia-Pacific is expected to grow rapidly at a CAGR of xx% during the forecast period 2021-2027. Due to increased health-care expenditures, Asia Pacific is expected to grow significantly during the forecast period. The market demand is estimated to be driven by the allocation of a significant amount of healthcare spending for hospitals and dispensing medicines to the elderly. These are the major key drivers that drives the growth of this region in the global market during the forecast period 2021-2027. The objective of the report is to present a comprehensive analysis of the Global Gene Therapy Market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants. PORTER, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The reports also help in understanding the Global Gene Therapy Market dynamic, structure by analyzing the market segments and project the Global Gene Therapy Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Gene Therapy Market make the report investor’s guide.

Global Gene Therapy Market Scope: Inquire before buying

Global Gene Therapy Market
Report Coverage Details
Base Year: 2020 Forecast Period: 2021-2027
Historical Data: 2016 to 2020 Market Size in 2020: US $ 4.86 Bn.
Forecast Period 2021 to 2027 CAGR: 27.9% Market Size in 2027: US $ 27.21 Bn.
Segments Covered: by Indication • Acute Lymphoblastic Leukemia (ALL) • Inherited Retinal Disease • Large B-cell Lymphoma • ADA-SCID • Melanoma (lesions) • Beta-Thalassemia Major/SCD • Head & Neck Squamous Cell Carcinoma • Peripheral Arterial Disease • Spinal Muscular Atrophy (SMA) • Others
by Vector Type • Lentivirus • AAV • Retrovirus & gamma Retrovirus • Modified Herpes Simplex Virus • Adenovirus • Non-viral Plasmid Vector

Global Gene Therapy Market, by Region

• North America • Europe • Asia Pacific • South America • Middle East and Africa

Global Gene Therapy Market Key Players

REGENXBIO, Inc. • Bayer • Oxford BioMedica plc • Dimension Therapeutics, Inc. • Bristol-Myers Squibb Company • SANOFI • Applied Genetic Technologies Corp • F. Hoffmann-La Roche Ltd. • Bluebird Bio, Inc. • Novartis AG • Taxus Cardium Pharmaceuticals Group, Inc. (Gene Biotherapeutics) • UniQure N.V. • Shire Plc; • Cellectis S.A. • Sangamo Therapeutics, Inc. • Orchard Therapeutics • Gilead Lifesciences, Inc. • Benitec Biopharma Ltd. • Sibiono GeneTech Co., Ltd. • Shanghai Sunway Biotech Co., Ltd • Gensight Biologics S.A. • Transgene • Calimmune, Inc • Epeius Biotechnologies Corp • Astellas Pharma, Inc • American Gene Technologies • BioMarin Pharmaceuticals, Inc. • Human Stem Cell Institute • Spark Therapeutics LLC • GlaxoSmithKline • Voyager Therapeutics

Frequently Asked Questions:

1] What segments are covered in Global Gene Therapy Market report? Ans. The segments covered in Global Gene Therapy Market report are based on Indication, and Vector Type. 2] Which region is expected to hold the highest share in the Global Gene Therapy Market? Ans. North America is expected to hold the highest share in the Global Gene Therapy Market. 3] Who are the top key players in the Global Gene Therapy Market? Ans. REGENXBIO, Inc., Bayer, Oxford BioMedica plc, Dimension Therapeutics, Inc., Bristol-Myers Squibb Company, SANOFI, and Applied Genetic Technologies Corp are the top key players in the Global Gene Therapy Market. 4] Which segment holds the largest market share in the Global Gene Therapy market by 2027? Ans. Spinal Muscular Atrophy (SMA) Indication segment hold the largest market share in the Global Gene Therapy market by 2027. 5] What is the market size of the Global Gene Therapy market by 2027? Ans. The market size of the Global Gene Therapy market is US $27.21 Bn. by 2027. 6] What was the market size of the Global Gene Therapy market in 2020? Ans. The market size of the Global Gene Therapy market was worth US $4.86 Bn. in 2020
1. Global Gene Therapy Market: Research Methodology 2. Global Gene Therapy Market: Executive Summary 2.1 Market Overview and Definitions 2.1.1. Introduction to Global Gene Therapy Market 2.2. Summary 2.1.1. Key Findings 2.1.2. Recommendations for Investors 2.1.3. Recommendations for Market Leaders 2.1.4. Recommendations for New Market Entry 3. Global Gene Therapy Market: Competitive Analysis 3.1 MMR Competition Matrix 3.1.1. Market Structure by region 3.1.2. Competitive Benchmarking of Key Players 3.2 Consolidation in the Market 3.2.1 M&A by region 3.3 Key Developments by Companies 3.4 Market Drivers 3.5 Market Restraints 3.6 Market Opportunities 3.7 Market Challenges 3.8 Market Dynamics 3.9 PORTERS Five Forces Analysis 3.10 PESTLE 3.11 Regulatory Landscape by region • North America • Europe • Asia Pacific • The Middle East and Africa • Latin America 3.12 COVID-19 Impact 4. Global Gene Therapy Market Segmentation 4.1 Global Gene Therapy Market, by Indication (2020-2027) • Acute Lymphoblastic Leukemia (ALL) • Inherited Retinal Disease • Large B-cell Lymphoma • ADA-SCID • Melanoma (lesions) • Beta-Thalassemia Major/SCD • Head & Neck Squamous Cell Carcinoma • Peripheral Arterial Disease • Spinal Muscular Atrophy (SMA) • Others 4.2 Global Gene Therapy Market, by Vector Type (2020-2027) • Lentivirus • AAV • Retrovirus & gamma Retrovirus • Modified Herpes Simplex Virus • Adenovirus • Non-viral Plasmid Vector 5. North America Gene Therapy Market (2020-2027) 5.1 Global Gene Therapy Market, by Indication (2020-2027) • Acute Lymphoblastic Leukemia (ALL) • Inherited Retinal Disease • Large B-cell Lymphoma • ADA-SCID • Melanoma (lesions) • Beta-Thalassemia Major/SCD • Head & Neck Squamous Cell Carcinoma • Peripheral Arterial Disease • Spinal Muscular Atrophy (SMA) • Others 5.2 Global Gene Therapy Market, by Vector Type (2020-2027) • Lentivirus • AAV • Retrovirus & gamma Retrovirus • Modified Herpes Simplex Virus • Adenovirus • Non-viral Plasmid Vector 5.3 North America Gene Therapy Market, by Country (2020-2027) • United States • Canada • Mexico 6. Asia Pacific Gene Therapy Market (2020-2027) 6.1. Asia Pacific Gene Therapy Market, by Indication (2020-2027) 6.2. Asia Pacific Gene Therapy Market, by Vector Type (2020-2027) 6.3. Asia Pacific Gene Therapy Market, by Country (2020-2027) • China • India • Japan • South Korea • Australia • ASEAN • Rest Of APAC 7. Middle East and Africa Gene Therapy Market (2020-2027) 7.1 Middle East and Africa Gene Therapy Market, by Indication (2020-2027) 7.2. Middle East and Africa Gene Therapy Market, by Vector Type (2020-2027) 7.3. Middle East and Africa Gene Therapy Market, by Country (2020-2027) • South Africa • GCC • Egypt • Nigeria • Rest Of ME&A 8. Latin America Gene Therapy Market (2020-2027) 8.1. Latin America Gene Therapy Market, by Indication (2020-2027) 8.2. Latin America Gene Therapy Market, by Vector Type (2020-2027) 8.3. Latin America Gene Therapy Market, by Country (2020-2027) • Brazil • Argentina • Rest Of Latin America 9. European Gene Therapy Market (2020-2027) 9.1. European Gene Therapy Market, by Indication (2020-2027) 9.2. European Gene Therapy Market, by Vector Type (2020-2027) 9.3. European Gene Therapy Market, by Country (2020-2027) • UK • France • Germany • Italy • Spain • Sweden • Austria • Rest Of Europe 10. Company Profile: Key players 10.1. REGENXBIO, Inc. 10.1.1. Company Overview 10.1.2. Financial Overview 10.1.3. Global Presence 10.1.4. Capacity Portfolio 10.1.5. Business Strategy 10.1.6. Recent Developments 10.2. Bayer 10.3. Oxford BioMedica plc 10.4. Dimension Therapeutics, Inc. 10.5. Bristol-Myers Squibb Company 10.6. SANOFI 10.7. Applied Genetic Technologies Corp 10.8. F. Hoffmann-La Roche Ltd. 10.9. Bluebird Bio, Inc. 10.10. Novartis AG 10.11. Taxus Cardium Pharmaceuticals Group, Inc. (Gene Biotherapeutics) 10.12. UniQure N.V. 10.13. Shire Plc; 10.14. Cellectis S.A. 10.15. Sangamo Therapeutics, Inc. 10.16. Orchard Therapeutics 10.17. Gilead Lifesciences, Inc. 10.18. Benitec Biopharma Ltd. 10.19. Sibiono GeneTech Co., Ltd. 10.20. Shanghai Sunway Biotech Co., Ltd 10.21. Gensight Biologics S.A. 10.22. Transgene 10.23. Calimmune, Inc 10.24. Epeius Biotechnologies Corp 10.25. Astellas Pharma, Inc 10.26. American Gene Technologies 10.27. BioMarin Pharmaceuticals, Inc. 10.28. Human Stem Cell Institute 10.29. Spark Therapeutics LLC 10.30. GlaxoSmithKline 10.31. Voyager Therapeutics

About This Report

Report ID 85074
Category Healthcare
Published Date March 2021
Updated Date Oct 2021
Contact Us